Vertex Pharmaceuticals (VRTX) Tax Provisions (2011 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Tax Provisions of $221.5 million for Q1 2026, up 163.38% year-over-year from $84.1 million in Q1 2025, and up 58.33% quarter-over-quarter from $139.9 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Tax Provisions (2011 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Tax Provisions history runs 16 years deep, the most recent figure standing at $221.5 million for Q1 2026.
- In Q1 2026, Tax Provisions rose 163.38% year-over-year to $221.5 million; the TTM figure through Mar 2026 stood at $827.4 million (up 20.14% YoY), while the FY2025 annual figure was $690.0 million, down 12.0% from the prior year.
- Tax Provisions for Q1 2026 stood at $221.5 million, up from $139.9 million in the prior quarter.
- The five-year high for Tax Provisions was $257.9 million in Q4 2022, with the low at $84.1 million in Q1 2025.
- The 5-year median for Tax Provisions is $202.4 million (2024), against an average of $198.0 million.
- The sharpest annual moves came in 2022 and 2025: Tax Provisions jumped 292.36% in 2022, then plunged 53.15% in 2025.
- Vertex Pharmaceuticals' Tax Provisions stood at $257.9 million in 2022, then slumped by 30.67% to $178.8 million in 2023, then climbed by 25.0% to $223.5 million in 2024, then slumped by 37.4% to $139.9 million in 2025, then surged by 58.33% to $221.5 million in 2026.
- Business Quant data shows VRTX's Tax Provisions at $221.5 million in Q1 2026, $139.9 million in Q4 2025, and $215.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 292.00 Mn |
| Mar 31, 2026 | 221.50 Mn |
| Dec 31, 2025 | 139.90 Mn |
| Sep 30, 2025 | 215.90 Mn |
| Jun 30, 2025 | 250.10 Mn |
| Mar 31, 2025 | 84.10 Mn |
| Dec 31, 2024 | 223.50 Mn |
| Sep 30, 2024 | 178.70 Mn |
| Jun 30, 2024 | 202.40 Mn |
| Mar 31, 2024 | 179.50 Mn |
| Dec 31, 2023 | 178.80 Mn |
| Sep 30, 2023 | 143.90 Mn |
| Jun 30, 2023 | 245.80 Mn |
| Mar 31, 2023 | 191.70 Mn |
| Dec 31, 2022 | 257.90 Mn |
| Sep 30, 2022 | 245.90 Mn |
| Jun 30, 2022 | 213.90 Mn |
| Mar 31, 2022 | 192.70 Mn |
| Dec 31, 2021 | 100.80 Mn |
| Sep 30, 2021 | 230.90 Mn |